Administration of tocilizumab also reduces IL-6-mediated tumor growth, breast CSCs, and the development of secondary metastases in a PTEN-/HER2+/trastuzumab-resistant xenograft mouse model (122). This evidence concerns the gene PTEN and neoplasm.